Compass Pathways' push for scalable psilocybin treatment centers on whether psychotherapy should remain essential to COMP360-assisted care

Compass Pathways sits at the center of a dispute over whether psilocybin treatment can be scaled by reducing or removing formal psychotherapy from the care model. The core issue is not psilocybin itself alone, but how COMP360 is expected to be delivered, supervised, and reimbursed if regulators approve it for mental health treatment. Supporters of a leaner model emphasize cost, clinic throughput, and commercial viability, especially because long therapist time makes psychedelic care expensive and hard to expand. Critics warn that minimizing therapy could weaken patient support, increase risk, and shift psilocybin treatment toward a narrowly medicalized protocol that overlooks preparation, meaning-making, and integration. The controversy matters because Compass is one of the most influential companies in the psilocybin sector. Its decisions around trial design, therapist involvement, and treatment delivery could shape reimbursement, regulation, and the standard of care across the broader psychedelic industry.